IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this article

Une approche hedonique de la formation des prix des médicaments remboursables

  • Stéphane Jacobzonne
  • Edouard Martin
  • Vincent Perrin
  • Julien Werle
Registered author(s):

    [fre] Une approche hédonique de la formation des prix des médicaments remboursables par Stéphane Jacobzone, Edouard Martin, Vincent Perrin et Julien Werle Une modélisation hédonique permet de formaliser le processus de formation des prix dans le cas du médicament remboursable. Les données utilisées couvrent 24 % du marché français sur la période 1980-1993, permettent de décrire les propriétés physico-chimiques des produits, et ont été appariées avec des données issues d'enquêtes auprès des entreprises. Elles couvrent deux classes thérapeutiques (antiulcéreux et pansements gastro-intestinaux, antihypertenseurs). La moitié, voire les deux tiers, de la variance des prix en coupe peut être expliquée par les caractéristiques chimiques et pharmacologiques des produits ainsi que par le conditionnement. L'estimation sur données de panel permet d'obtenir des indices de prix hédoniques, en séparant les effets de renouvellement de produits de ceux de déformation du marché. Ces indices ajustés par la qualité évoluent plus rapidement que les indices statistiques officiels, de l'ordre de 20 %. La dynamique des prix est également liée au caractère du produit, innovant ou non. Ce biais, original au niveau international, serait lié aux possibilités de substitutions stratégiques entre produits, au bénéfice de produits plus récents et plus coûteux. [eng] Reimboursed drugs price setting: a hedonic approach by Stéphane Jacobzone, Edouard Martin, Vincent Perrin and Julien Werle A hedonic pricing model is used to describe price setting in the case of reimbursed drugs in France. The data used cover 24 % of the French market over the period 1980-1993, allow for a detailed description of physical and chemical properties of the products, and have been matched with business survey data. They pertain to two main therapeutic classes (anti-ulcer drugs, antihypertensive drugs). lucts, from the effects of changing market structure. These indices, which are adjusted for quality, grow more rapidly than official indices, the bias averaging 20 %. Price dynamics also depend on whether the product is innovative or not. This effect has not been found in other studies. It suggests that given their environment firms have an incentive to introduce, new - and therefore more expensive- drugs.

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: no

    File URL:
    Download Restriction: no

    Article provided by Programme National Persée in its journal Économie & prévision.

    Volume (Year): 129 (1997)
    Issue (Month): 3 ()
    Pages: 73-99

    in new window

    Handle: RePEc:prs:ecoprv:ecop_0249-4744_1997_num_129_3_5865
    Note: DOI:10.3406/ecop.1997.5865
    Contact details of provider: Web page:

    References listed on IDEAS
    Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

    as in new window
    1. Jensen, Gail A & Morrisey, Michael A, 1990. "Group Health Insurance: A Hedonic Price Approach," The Review of Economics and Statistics, MIT Press, vol. 72(1), pages 38-44, February.
    2. Bitros, George C & Panas, Epaminondas E, 1988. "Measuring Product Prices under Conditions of Quality Change: The Case of Passenger Cars in Greece," Journal of Industrial Economics, Wiley Blackwell, vol. 37(2), pages 167-86, December.
    3. Griliches, Zvi & Cockburn, Iain, 1994. "Generics and New Goods in Pharmaceutical Price Indexes," American Economic Review, American Economic Association, vol. 84(5), pages 1213-32, December.
    4. Cowling, Keith & Cubbin, John, 1972. "Hedonic Price Indexes for United Kingdom Cars," Economic Journal, Royal Economic Society, vol. 82(327), pages 963-78, September.
    5. Abbott, Thomas III, 1995. "Price regulation in the pharmaceutical industry: Prescription or placebo?," Journal of Health Economics, Elsevier, vol. 14(5), pages 551-565, December.
    6. Feenstra, Robert C, 1997. "Generics and New Goods in Pharmaceutical Price Indexes: Comment," American Economic Review, American Economic Association, vol. 87(4), pages 760-67, September.
    7. Judith K. Hellerstein, 1994. "The Demand for Post-Patent Prescription Pharmaceuticals," NBER Working Papers 4981, National Bureau of Economic Research, Inc.
    8. Kelvin J. Lancaster, 1966. "A New Approach to Consumer Theory," Journal of Political Economy, University of Chicago Press, vol. 74, pages 132.
    9. Franklin M. Fisher & Zvi Griliches, 1995. "Aggregate Price Indices, New Goods, and Generics," The Quarterly Journal of Economics, Oxford University Press, vol. 110(1), pages 229-244.
    10. Yves Guillotin & Patrick Sevestre, 1994. "Estimations de fonctions de gains sur données de panel : endogéneité du capital humain et effets de la sélection," Économie et Prévision, Programme National Persée, vol. 116(5), pages 119-135.
    11. Brent R. Moulton, 1996. "Bias in the Consumer Price Index: What Is the Evidence?," Journal of Economic Perspectives, American Economic Association, vol. 10(4), pages 159-177, Fall.
    Full references (including those not matched with items on IDEAS)

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:prs:ecoprv:ecop_0249-4744_1997_num_129_3_5865. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Equipe PERSEE)

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.